A Health Podyssey

← A Health Podyssey20 okt · 22 min

The Real Savings From Generic Drugs: What Medicare Part D Data Reveals | CBO's Scott Laughery

The Real Savings From Generic Drugs: What Medicare Part D Data Reveals | CBO's Scott Laughery20 okt22 min

This episode is brought to you by Semafor Healthcare.

Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.

Health Affairs Publishing’s Rob Lott speaks to Scott Laughery of the Congressional Budget Office about new research examining how generic drug entry affects net prescription drug prices and spending in Medicare Part D.

Their conversation explores the often-hidden role of rebates, how generic competition reshapes drug markets, and what newly available data reveal about savings after loss of exclusivity.

Order the October 2026 issue of Health Affairs.

Sign up for our free Health Affairs newsletters to stay up to date on health policy news and analysis.

Subscribe to Semafor Healthcare for free.